Top Medical News
Yesterday
Therapeutic care appears to improve anxiety and depression, and reduce fatigue in breast cancer patients undergoing chemotherapy, a new clinical trial has shown.
Yesterday
There appears to be an increased relative risk of small bowel adenocarcinomas in Crohn’s disease (CD) and of small bowel neuroendocrine tumours in both CD and ulcerative colitis, a study suggests.
Yesterday
Age appears to not significantly impact treatments and outcomes for hepatocellular carcinoma (HCC), a new study reveals. Survival is comparable between older and younger patients, and equally active treatments should be administered to both age groups.
2 days ago
Low-level occupational exposure to crystalline silica is associated with increased risk of mortality from respiratory diseases, pulmonary heart disease, lung cancer and ischaemic heart disease, among other complications, a new study has found.
Christina Lau, 3 days ago

Patients with locally advanced cervical cancer should not be routinely treated with neoadjuvant chemotherapy (NACT) followed by surgery as this approach does not improve disease-free survival (DFS) or overall survival (OS) vs standard chemoradiotherapy (CRT), according to results of a phase III trial.

Jackey Suen, 3 days ago

The risk of recurrence in patients with resected stage III BRAF-mutant melanoma can be reduced with adjuvant BRAF inhibitor and/or MEK inhibitor therapy, according to two phase III studies presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain.

Tristan Manalac, 3 days ago
Sweet and traditional Chinese dietary patterns appear to significantly reduce the risk of breast cancer in both pre- and postmenopausal Chinese women, a new population-based study has shown.
Special Reports
Dr. Alexander Drilon, 19 Jul 2017
With the dramatic evolution of sequencing technology and emergence of effective targeted therapies, using a comprehensive molecular approach to guide treatment decisions is becoming more accessible and applicable in the clinic. At the recent Foundation Medicine meeting in Hong Kong, Dr Alexander Drilon, clinical director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, US, discussed the current landscape and potential benefits of comprehensive molecular profiling in non-small cell lung cancer (NSCLC).
Prof. Ignatius Ou Sai Hong, Dr. James Suh, Dr. Wong Seng Weng, Dr. Amit Verma, 14 May 2017
As targeted cancer therapy options are increasing, it is becoming more important to choose the most appropriate treatment for patients with cancer. At a Roche-sponsored symposium held during the 2nd ESMO Asia Congress in Singapore, four experts discussed the potential of comprehensive genomic profiling (CGP) for personalizing cancer care and helping healthcare professionals to make the best treatment decisions for individual patients.
Dr. Ross Soo, Prof. James Chih-Hsin Yang, Prof. Tony Mok, Prof. Fred Hirsch, 28 Mar 2017
Classification and treatment of non-small cell lung cancer (NSCLC) has greatly evolved in recent years. A better understanding of this complex malignancy has led to a shift from histologic diagnosis to more accurate subclassification using molecular screening which, in turn, led to the transition from empiric treatment to molecular target therapy. At the European Society for Medical Oncology (ESMO) Asia 2016 Congress in Singapore, Dr Ross Soo from the National University Cancer Institute, Singapore, Professor James Chih-Hsin Yang from the National Taiwan University Hospital, Taiwan, Professor Tony Mok from The Chinese University of Hong Kong, Hong Kong, and Professor Fred Hirsch from the University of Colorado Cancer Center, Colorado, US presented therapeutic biomarker-driven strategies for improving outcomes in patients with NSCLC. The discussion focused on the role and impact of molecular target therapy using epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) biomarkers and T-cell-based immunotherapy in coming up with algorithms to guide clinicians in selecting the best treatment regimen for each patient.
14 Mar 2017
Over 20 leading surgical and medical oncologists from Singapore attended a dinner meeting on the Neoadjuvant treatment of early breast cancer (eBC). Co-chaired by Dr Veronique Tan (National Cancer Centre, Singapore) and Dr Elaine Lim (National Cancer Centre, Singapore), the meeting served as a platform to discuss the role of neoadjuvant therapy in eBC management. Guest speakers, Professor J. Michael Dixon OBE (Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom) and Dr Rebecca Dent (National Cancer Centre, Singapore) shared their perspectives on the benefits of neoadjuvant therapy in different BC subtypes.
31 Jan 2017
At the launch of Caris Molecular Intelligence® in Malaysia, Dr Andrew Dean, Head of Oncology at the St John of God Subianco Hospital, Perth, shared with the audience on molecular profiling and its benefits, with a focus on the Caris Molecular Intelligence® service.
16 Dec 2016
KEYTRUDA – Pembrolizumab 100 mg/4 mL soln for inj – Merck Sharp & Dohme
Yao-Hua Law, PhD, 15 Dec 2016
The genomics of cancer patients affect their responses to therapies. Some genomic alterations in cancer genes are better treated with targeted therapies, and physicians informed by genomic profiles of their patients can better decide on optimal treatments. Next-generation sequencing (NGS) technology has facilitated rapid and inexpensive gene sequencing for clinical use. This article discusses NGS applications for cancer management, focusing on comprehensive genomic profiling (CGP).
Conference Reports
Christina Lau, 18 Sep 2017

Patients with locally advanced cervical cancer should not be routinely treated with neoadjuvant chemotherapy (NACT) followed by surgery as this approach does not improve disease-free survival (DFS) or overall survival (OS) vs standard chemoradiotherapy (CRT), according to results of a phase III trial.

Jackey Suen, 18 Sep 2017

The risk of recurrence in patients with resected stage III BRAF-mutant melanoma can be reduced with adjuvant BRAF inhibitor and/or MEK inhibitor therapy, according to two phase III studies presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain.

Dr. Joseph Delano Fule Robles, 15 Sep 2017

Combination therapy with ramucirumab and docetaxel offers a progression-free survival (PFS) advantage over docetaxel alone in patients with advanced or metastatic urothelial carcinoma (UC), according to results of the phase III RANGE trial presented at the European Society of Medical Oncology  (ESMO) 2017 Congress held in Madrid, Spain. 

Jenny Ng, 14 Sep 2017

Adding taselisib to standard neoadjuvant letrozole therapy significantly improves overall response rate (ORR) in postmenopausal patients with oestrogen receptor (ER)-positive, HER2-negative early-stage breast cancer, according to data from the phase II LORELEI trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress held in Madrid, Spain. 

Christina Lau, 14 Sep 2017

Nivolumab plus ipilimumab significantly improves overall survival (OS) vs sunitinib in patients with intermediate- or poor-risk advanced renal cell carcinoma (RCC), according to results of the first-line CheckMate 214 study presented at the European Society for Medical Oncology (ESMO) 2017 Congress held in Madrid, Spain.

14 Sep 2017
Slideshow: Highlights from the European Society for Medical Oncology (ESMO) Congress 2017
Jackey Suen, 13 Sep 2017

Adding the CDK4/6 inhibitor abemaciclib to endocrine therapy improves progression-free survival (PFS) in first-line treatment of hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer, according to results of the phase III MONARCH 3 study presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain. [ESMO 2017, abstract 236O_PR]

Product Highlights
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD